Pacira Pharmaceuticals buy Barclays PLC
Start price
23.10.23
/
50%
€26.20
Target price
23.10.24
€53.51
Performance (%)
6.11%
Price
05.06.24
€27.40
Summary
This prediction is currently active. With a performance of 6.11%, the BUY prediction by Barclays_PLC for Pacira Pharmaceuticals is trending in the right direction. This prediction currently runs until 23.10.24. The prediction end date can be changed by Barclays_PLC at any time. Barclays_PLC has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Pacira Pharmaceuticals | 3.008% | 3.008% |
iShares Core DAX® | 0.597% | 3.083% |
iShares Nasdaq 100 | 0.899% | 5.338% |
iShares Nikkei 225® | 1.775% | -1.206% |
iShares S&P 500 | 0.990% | 3.500% |
Comments by Barclays_PLC for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Barclays PLC from $60.00 to $57.00. They now have an "overweight" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Stopped prediction by Barclays_PLC for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€26.80
08.05.24
08.05.24
€35.35
08.05.25
08.05.25
3.73%
05.06.24
05.06.24